ArticlePreventive medicine2017
Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.
Article in Preventive medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis.Public health · 2020Pooled it
- Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial.Papillomavirus research (Amsterdam, Netherlands) · 2020Trial
- The Predictive Impact of HPV Genotypes, Tumor Suppressors and Local Immune Response in the Regression of Cervical Intraepithelial Neoplasia 2-3: A Prospective Population-Based Cohort Study.International journal of molecular sciences · 2025Article
- Exploring the Intricacies of Cervical Intraepithelial Neoplasia and Its Connection with HPV: A Narrative Review.Iranian journal of public health · 2024Review
- Article
- Development and validation of artificial intelligence-based analysis software to support screening system of cervical intraepithelial neoplasia.Scientific reports · 2024Article
- Using the Incidence of Cervical Cancer Precursors to Assess the Impact of HPV Vaccination Efforts in Kentucky.Journal of registry management · 2023Article
- Median Age at HPV Infection Among Women in the United States: A Model-Based Analysis Informed by Real-world Data.Open forum infectious diseases · 2021Article
- The role and utility of population-based cancer registries in cervical cancer surveillance and control.Preventive medicine · 2021Article
- Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.International journal of cancer · 2020Article
- Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.International journal of cancer · 2019Article
- Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.MMWR. Morbidity and mortality weekly report · 2019Article
- Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
Surveillance of cervical intraepithelial neoplasia grade III (CIN III) and adenocarcinoma in situ (AIS) is important for determining the burden of a preventable disease, identifying effects of vaccination on future diagnoses, and developing targeted programs. We analyzed population-based rates of high-grade cervical cancer precursor lesions using data from four central cancer registries (diagnosis years 2009-2012 from Louisiana, Kentucky, Michigan, and diagnosis years 2011-2012 from Los Angeles) by age, race, and histology. We also compared rates of precursors to invasive cancers. With 4 complete years of data from Michigan, we were able to conduct a trend analysis for that state. Data analysis was conducted in Atlanta during 2016. Kentucky reported the highest rate of CIN III/AIS (69.8), followed by Michigan (55.4), Louisiana (42.3), and Los Angeles (19.2). CIN III/AIS rates declined among women in Michigan by 37% each year for women aged 15-19, 14% for those aged 20-24, and 7% for those aged 25-29. Rates of CIN III/AIS vary by registry, and were higher than invasive cancer. In Michigan, declines in CIN III/AIS among women aged 15-29 are likely related in part to updated screening recommendations, and to the impact of human papillomavirus vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.